Navigation Links
China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
Date:5/26/2009

HARBIN, China, May 26 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced that it recently obtained production approval from the State Food and Drug Administration (SFDA) in China for two of its newly developed drugs.

Acyclovir gel is used to treat the skin infection due to varicella-zoster virus and the herpes simplex virus. Shuanghuanglian suppositories helps relieve cold and flu symptoms such as fever, cough and sore throat pain. It can also be used to treat upper respiratory infections and pneumonia. Both of the products are for common diseases, and should benefit as a result of the rapidly expanded rural health market, especially after China's recent reform of the insurance system. They will be introduced to the market in the third quarter of 2009.

China Sky One Medical started R&D of the two drugs in 2003 and submitted the applications for SFDA approval in early 2007. The document numbers for the drugs are H20093399 and Z20093134. In all, China Sky One Medical has received production approval for 25 products since January 2008, including six new products in 2009. Currently, the Company has over 20 products in the application process under SFDA review.

Recently the Company also received the approval from SFDA for Diclofenac Sodium suppositories to enter the clinical trial, with the document number 2009L02108. This drug is used to treat rheumatoid arthritis and to relieve pain after operations and fever.

"We are excited about our new drug approvals, which are a testament to our outstanding R&D capability and our understanding of the pharmaceutical market in China," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "We will continue to develop exciting new products in the future and are committed to increasing our pipeline and R&D capabilities."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-451-5399-4069
     Email: china_sky_one@yahoo.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug
2. The Hamner Institutes Announce Partnership With China Medical City
3. China Sky One Medical, Inc. Appoints Pricewaterhouse Coopers to Help Develop a SOX 404 Compliance Program
4. Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China
5. China Biologic Products Announces Strong First Quarter 2009 Results
6. China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results
7. China Biologic Products Announces 2009 First Quarter Results Conference Call
8. China Biologic Products to Present at CCG IRs China Rising Conference and Oppenheimers China Dragon Call Conference in New York
9. China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results
10. China-Biotics, Inc. to Present at CCG Investor Relations China Rising Conference
11. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
Breaking Biology News(10 mins):